The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Kymera Therapeutics Inc shares valued at $13,955,348 were purchased by BVF PARTNERS L P/IL on Jun 30 ’25. At $44.00 per share, BVF PARTNERS L P/IL acquired 317,167 shares. The insider’s holdings grew to 2,798,795 shares worth approximately $124.63 million following the completion of this transaction.
Also, BAKER BROS. ADVISORS LP purchased 655,500 shares, netting a total of over 28,842,000 in proceeds. Following the buying of shares at $44.00 each, the insider now holds 6,117,295 shares.
Before that, Ridloff Elena had sold 4,500 shares from its account. In a trade valued at $225,000, the Director traded Kymera Therapeutics Inc shares for $50.00 each. Upon closing the transaction, the insider’s holdings decreased to 4,500 shares, worth approximately $0.0.
As published in a research note from Morgan Stanley on June 03, 2025, Kymera Therapeutics Inc [KYMR] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $79. Analysts at B. Riley Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early June. As of June 02, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for KYMR.
Analyzing KYMR Stock Performance
On last trading session,, Kymera Therapeutics Inc [NASDAQ: KYMR] rose 0.20% to $44.53. The stock’s lowest price that day was $44.075, but it reached a high of $45.46 in the same session. During the last five days, there has been a drop of approximately -4.17%. Over the course of the year, Kymera Therapeutics Inc shares have jumped approximately 49.18%. Shares of the company reached a 52-week high of $50.27 on 06/11/25 and a 52-week low of $19.44 on 04/09/25.
Support And Resistance Levels for Kymera Therapeutics Inc (KYMR)
According to the 24-hour chart, there is a support level at 43.92, which, if violated, would cause prices to drop to 43.30. In the upper region, resistance lies at 45.30. The next price resistance is at 46.07. RSI (Relative Strength Index) is 57.54 on the 14-day chart, showing neutral technical sentiment.
Is Kymera Therapeutics Inc subject to short interest?
Stocks of Kymera Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.59 million shares to 7.58 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 7.0 million shares. A jump of 7.75% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.15 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.15.
Which companies own the most shares of Kymera Therapeutics Inc (KYMR)?
In terms of Kymera Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 59 in the next 12 months, up nearly 32.76% from the previous closing price of $44.44. Analysts anticipate Kymera Therapeutics Inc stock to reach 64 by 2025, with the lowest price target being 53. In spite of this, 8 analysts ranked Kymera Therapeutics Inc stock as Buy at the end of 2025. On March 13, 2025, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $52.
